Reneuron Group (RENE)

 

RENE Share PerformanceMore

52 week high6.5000 15/07/15
52 week low2.2615 08/12/15
52 week change -1.8000 (-32.73%)
4 week volume50,061,310 29/04/16

Media for (RENE)

Presenter: Michael Hunt, CEO
04/02/2015

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Are Today’s Double-Digit Rises Just The Start For Filtronic Plc, Angle plc And ReNeuron Group Plc?

Shares in Filtronic (LSE:FTC) have soared by over 20% today after it announced a major new contract win. The designer a...

RENE says first patient treated in RP clinical trial

ReNeuron said the first patient has been treated with the company's cell therapy candidate for the blindness-causing diseas...

First Patient Treated in RP Clinical Trial

Miscellaneous medium priority announcements

ReNeuron Relocates to South Wales

Miscellaneous medium priority announcements

Director Deals - ReNeuron Group PLC (RENE)

Michael Hunt, Financial Director, exercised 5,361,673 shares in the company on the 3rd February 2016 at a price of 1.00p. Th...

Director Deals - ReNeuron Group PLC (RENE)

Michael Hunt, Financial Director, exercised 5,361,673 shares in the company on the 3rd February 2016 at a price of 1.00p. Th...

Director Deals - ReNeuron Group PLC (RENE)

Michael Hunt, Financial Director, exercised 5,361,673 shares in the company on the 3rd February 2016 at a price of 1.00p. Th...

Director's Dealings

Notification of issuers, persons discharging managerial responsibilities and their connected persons in respect of transactions conducted in their own account in shares of the issuer

Fundamental DataMore

EPS-0.5
Dividend yield0 %

Equity Research (RENE)

edison investment research
ReNeuron Group plc
24/03/2016
ReNeuron has treated the first patient in its US Phase I/II clinical trial with its cell therapy candidate for the blindness-causing disease retinitis pigmentosa (RP). This is a significant step...
edison investment research
ReNeuron Group plc
29/10/2015
With significant financial resources able to support an extensive clinical development programme over the next three to four years, ReNeuron is well-positioned to determine the true value of its cell...
edison investment research
ReNeuron Group plc
23/04/2015
ReNeuron presented two-year follow-up data from the PISCES study in disabled stroke patients, which confirm the potential for long-term benefits from treatment with its CTX neural stem cells....

Latest discussion posts More

  • Soon 4p then onto 5p .....

    ...dont know if the recovery has started, but looking good if bid rises to follow ask. Fingers crossed as we should return to 6p by end June, prior to update. Slowly slowly ...
    25-May-2016
    fredd1eboy
  • Re: bit of info

    Notice the early trade of #17k wasnt listed until end of play today. I dont know! mm's silly games, what would you do with them!
    24-May-2016
    fredd1eboy
  • Re: bit of info

    After speed reading the contents of you links mol, I feel I have known Ester Kitto all my life. On a serious note, did you notice today's trading pattern. Buys all day and ...
    23-May-2016
    fredd1eboy

Users' HoldingsMore

Users who hold Reneuron Group also hold..
LLOYDS GRP.15%
BARCLAYS14%
BP13%
GLAXOSMITHKLINE11%
ROCKHOPPER11%

Codes & Symbols

ISINGB00B0DZML60
SymbolsRENE, LSE:RENE, RENE.L, RENE:LN, LON:RENE, XLON:RENE